In healthy cells, BAX protein is largely found in the cytosol. However, upon initiation of apoptotic signaling, Bax undergoes a conformational shift and becomes organelle membrane-associated, in particular with the mitochondrial membrane. The main BAX Remdesivir GS-5734 effect involves the induction of opening of the mitochondrial voltage-dependent anion channel that results in the release of pro-apoptotic factors from the mitochondria, leading to the activation of CASPs. The results showed differential Bax/Bcl-2 ratio gene expression in PBMCs from carriers of different Ala16Val-SOD2 genotypes exposed to MTX. Whereas the BAX/Bcl-2 ratio was below one in AA- and AV-PBMCs indicating a tendency to antiapoptotic events, VV-PBMCs showed a higher Bax/Bcl-2 ratio indicating the maintenance of cellular apoptosis. Therefore, these results confirmed the influence of Ala16Val-SOD2 on PBMC susceptibility to MTX exposure. Experimental studies suggest that statins, a well-established group of cholesterol-lowering drugs, may have antitumor properties against this common cancer.. Statins reduce cholesterol biosynthesis in the liver by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme-A reductase, the rate-limiting enzyme in the mevalonate pathway. In addition to cholesterol, this pathway produces isoprenoids that are critical for regulation of cell growth. The pathway is also essential for tumor promoting effects of oncogene p53. Further, cholesterol is a critical component of intracellular lipid-rafts, which are crucial for intracellular signaling. Thus statins’ anticancer effects have a biologically plausible background. Despite promising preclinical results, there is no clear association between statin use and breast cancer incidence. However, some recent studies have reported lowered overall cancer mortality among statin users, including one study that reported decreased breast cancer mortality among prediagnostic statin users, and other studies have suggested that statin use is associated with improved recurrence-free survival among breast cancer patients. Therefore statins may exert a greater effect on cancer progression versus initiation. We studied the association between statin use and breast cancer mortality among breast cancer patients in a nationwide population-based cohort. Finnish health care units, the Finnish Cancer Registry has good national coverage, including over 99% of cancer cases in Finland. The information on breast cancer cases included the date of diagnosis, tumor stage, tumor morphology, initial treatment selection and date and cause of death. Information on tumor hormone receptor status or screening history was not available. However, the screening participation rate for breast cancer screening in Finland has been reported to be up to 90%.